About Realm Therapeutics
Realm Therapeutics is a company based in Malvern (United States) founded in 1997 was acquired by ESSA Pharma in May 2019. Realm Therapeutics operates in a competitive market with competitors including Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter Malvern, United States
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Realm Therapeutics Plc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$20.5 M (USD), Post-IPO
Oct 24, 2017
-
Investors
ESSA Pharma
& 7 more
-
Employee Count
Employee Count
-
Acquired by
ESSA Pharma
(May 16, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Realm Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Realm Therapeutics
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $20.5M
-
First Round
First Round
(17 Oct 2007)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2017 | Amount | Post-IPO - Realm Therapeutics | Valuation |
investors |
|
| Sep, 2017 | Amount | Post-IPO - Realm Therapeutics | Valuation |
investors |
|
| Apr, 2010 | Amount | Debt – Venture - Realm Therapeutics | Valuation |
investors |
Investors in Realm Therapeutics
Realm Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include ESSA Pharma, Orbimed and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Early stage venture capital firm investing in US
|
Founded Year | Domain | Location | |
|
US private equity investments are managed by BVF Partners.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Realm Therapeutics
Financial Statements - Realm Therapeutics
Realm Therapeutics Comparisons
Competitors of Realm Therapeutics
Realm Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| domain | founded_year | HQ Location |
GPCR drug discovery platform is developed for multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for allergic and inflammatory diseases are developed.
|
Frequently Asked Questions about Realm Therapeutics
Realm Therapeutics was founded in 1997 and raised its 1st funding round 10 years after it was founded.
Realm Therapeutics is headquartered in Malvern, United States. It is registered at Malvern, Pennsylvania, United States.
Realm Therapeutics (formerly known as PuriCore) is utilising its immunomodulatory formulations to develop small molecule therapies for inflammatory diseases with application in dermatology and ophthalmology. Its topical products in development include PR013, a topical solution for allergic conjunctivitis (eye inflammation) (Phase 1); PR022, a topical gel for atopic dermatitis (Phase 1).
Realm Therapeutics's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
Realm Therapeutics has 8 investors. Key investors include ESSA Pharma, Orbimed, RA Capital, Fulton Bank, and Abingworth.